Equillium, Inc. (EQ) stock
EQNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.32−0.10 (-7.04%)
Close on Nov 12, 2026Market cap $83.70MP/E –Yield –
Equillium r&d expenses
Research and development expenses are spending on new products and technology.
Equillium's R&D Expenses for the twelve months ending Sep 30, 2026 was $9.76M, down 47.6% year over year. For fiscal 2025 it was $12.84M, down 65.7% from the year before. The highest annual figure on record is $37.55M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.84M | -65.7% |
| FY2024 | Dec 31, 2024 | $37.43M | +1.1% |
| FY2023 | Dec 31, 2023 | $37.04M | -1.4% |
| FY2022 | Dec 31, 2022 | $37.55M | +42.3% |
| FY2021 | Dec 31, 2021 | $26.38M | +36.1% |
| FY2020 | Dec 31, 2020 | $19.38M | +9.9% |
| FY2019 | Dec 31, 2019 | $17.64M | +256.9% |
| FY2018 | Dec 31, 2018 | $4.94M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.49M | +91.2% |
| Q2 FY2026 | Jun 30, 2026 | $2.75M | -32.7% |
| Q1 FY2026 | Mar 31, 2026 | $2.99M | -49.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.54M | -79.0% |
| Q3 FY2025 | Sep 30, 2025 | $1.30M | -86.4% |
| Q2 FY2025 | Jun 30, 2025 | $4.08M | -62.2% |
| Q1 FY2025 | Mar 31, 2025 | $5.92M | -39.2% |
| Q4 FY2024 | Dec 31, 2024 | $7.32M | -20.4% |
| Q3 FY2024 | Sep 30, 2024 | $9.56M | +6.6% |
| Q2 FY2024 | Jun 30, 2024 | $10.81M | +12.5% |
| Q1 FY2024 | Mar 31, 2024 | $9.74M | +5.1% |
| Q4 FY2023 | Dec 31, 2023 | $9.18M | +7.7% |
| Q3 FY2023 | Sep 30, 2023 | $8.97M | +2.3% |
| Q2 FY2023 | Jun 30, 2023 | $9.61M | +1.3% |
| Q1 FY2023 | Mar 31, 2023 | $9.27M | -13.9% |
| Q4 FY2022 | Dec 31, 2022 | $8.53M | +12.9% |
| Q3 FY2022 | Sep 30, 2022 | $8.77M | +25.9% |
| Q2 FY2022 | Jun 30, 2022 | $9.49M | +58.5% |
| Q1 FY2022 | Mar 31, 2022 | $10.76M | +83.0% |
| Q4 FY2021 | Dec 31, 2021 | $7.55M | +15.0% |
| Q3 FY2021 | Sep 30, 2021 | $6.97M | +65.1% |
| Q2 FY2021 | Jun 30, 2021 | $5.99M | +53.7% |
| Q1 FY2021 | Mar 31, 2021 | $5.88M | +24.9% |
| Q4 FY2020 | Dec 31, 2020 | $6.57M | +20.5% |
| Q3 FY2020 | Sep 30, 2020 | $4.22M | +0.9% |
| Q2 FY2020 | Jun 30, 2020 | $3.89M | -8.4% |
| Q1 FY2020 | Mar 31, 2020 | $4.71M | +25.2% |
| Q4 FY2019 | Dec 31, 2019 | $5.45M | +116.4% |
| Q3 FY2019 | Sep 30, 2019 | $4.18M | +242.2% |
| Q2 FY2019 | Jun 30, 2019 | $4.25M | +687.0% |
| Q1 FY2019 | Mar 31, 2019 | $3.76M | +467.0% |
| Q4 FY2018 | Dec 31, 2018 | $2.52M | +4941.1% |
| Q3 FY2018 | Sep 30, 2018 | $1.22M | – |
| Q2 FY2018 | Jun 30, 2018 | $540.00K | – |
| Q1 FY2018 | Mar 31, 2018 | $663.00K | – |
| Q3 FY2017 | Sep 30, 2017 | $49.95K | – |
See a number that looks wrong?